With Rimidi’s Epidemic Monitoring Platform, originally built for health systems with EHR-integration to screen, monitor, and triage patients appropriately, employers can apply a more holistic return-to-work strategy.
ATLANTA (PRWEB)
June 12, 2020
Rimidi, a cloud-based software platform that enables personalized management of health conditions across populations, today unveiled its COVID-19 Population Monitoring Toolkit for employers to accurately assess workforce readiness as they begin to reopen among the coronavirus pandemic. The tool ensures the health and safety of individuals by offering businesses a holistic platform that combines symptom surveillance, testing and biometric monitoring to determine overall preparedness.
“While employers have started testing employees for COVID-19, testing is still an imperfect system. Results may take up to 72 hours and the cost of frequent workforce testing adds up fast, with each test costing roughly $100. To ensure employee safety and minimize operational disruption, employers need a strategic approach with testing and temperature checking being directed by screening data,” said Lucienne Ide, MD, PhD, founder of Rimidi. “With Rimidi’s Epidemic Monitoring Platform, originally built for health systems with EHR-integration to screen, monitor, and triage patients appropriately, employers can apply a more holistic return-to-work strategy.”
Through a partnership with CareTeam, an employee health services company with onsite or near-site clinics, as well as virtual health management, employers using the Rimidi Epidemic Monitoring platform can aggregate and analyze employee data to accurately assess their workforce’s readiness. By leveraging the real-time insights provided, employers can create a longitudinal record of the measures taken to protect their employees, while also strategically using testing and personal protective equipment resources.
“We are thrilled to partner with Rimidi to help organizations safely get their employees back to work during these unprecedented times. By giving employers a tool to compliantly monitor their workforce symptoms and potential COVID-exposure, in line with Centers for Disease Control and Prevention guidance, we are able to help employers continue to operate through these challenging times,” added Scott Parks, President, CareTeam.
Whether for healthcare staff, essential manufacturing employees, or office workers, the Rimidi Epidemic Monitoring Platform supports the necessary measures and tracking guidelines employers need to inform workforce readiness.
One company working with Rimidi and CareTeam is Tiger Fuel, a large distributor of petroleum energy products. CareTeam provides near-site clinic support for Tiger Fuel employees who may be referred to testing depending on their answers to the screening survey.
“COVID-19 has changed the workplace indefinitely. Historically, testing employees and asking personal health questions had been deemed too intrusive, but it’s now necessary to ensure the overall safety and well-being of teams. Using technology like the Rimidi Epidemic Monitoring platform, we are able to reopen the workplace in a safe and efficient way, while also working to prevent potential outbreaks on the job,” said Ryan Whitlock, Tiger Fuel’s human-resources director.
For more information on the COVID-19 Population Monitoring Toolkit or to see how the Epidemic Platform helps health systems triage and monitor patients appropriately, visit
rimidi.com/lp/employers-covid-19-monitoring-toolkit.
About Rimidi
Rimidi is a cloud-based software platform that enables personalized management of health conditions across populations. Created by doctors, Rimidi avoids the disconnect in connected care by combining patient-generated health data with clinical data from the EHR to drive patient-specific clinical insights and actions. The net effect is a better health system with optimized clinical workflows that enable better decisions, better relationships, better outcomes and ultimately a better healthcare system. For more information, visit rimidi.com and follow us on Facebook, Twitter and LinkedIn.
Share article on social media or email: